Jacques J Peschon

This inventor holds 11 USPTO granted patents and 6 published patent applications, plus 2 CIPO patents and 5 EPO patents. Top assignees: Amgen Inc., Amgen K-a, Inc., Kirin-Amgen, Inc.. Active years: 2006-2024.

USPTO Granted Patents = 11 (Patent Applications = 6)

% Patents Active = 100.0

CIPO Patents = 2

EPO Patents = 5 (Patent Applications = 4)

Average Co-Inventor Count = 3.8

ph-index = 6

Forward Citations = 90(Granted Patents)

Company Filing History:

Years Active: 2006-2024

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11858999 - IL-17 receptor A antigen binding proteins (2024-01-02),

2. 11180564 - IL-17 Receptor A antigen binding proteins (2021-11-23),

3. 10208122 - IL-17 receptor A antigen binding proteins (2019-02-19),

4. 9096673 - IL-17 receptor A antigen binding proteins (2015-08-04),

5. 8790648 - Methods of treating psoriasis using IL-17 receptor A antibodies (2014-07-29),

6. 8545842 - Polynucleotides encoding IL-17 receptor A antigen binding proteins (2013-10-01),

7. 8435518 - Methods of using IL-17 receptor a antibodies (2013-05-07),

8. 7939070 - IL-17 receptor A antigen binding proteins (2011-05-10),

9. 7833527 - Methods of treating psoriasis using IL-17 Receptor A antibodies (2010-11-16),

10. 7786284 - Polynucleotides encoding IL-17 receptor A antigen binding proteins (2010-08-31),

11. 7122183 - Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L (2006-10-17),

Title: Innovations by Jacques J Peschon: A Pioneer in IL-17 Receptor A Research

Introduction

Jacques J Peschon, a prominent inventor based in Seattle, WA, has made significant contributions to the field of immunology with a focus on IL-17 receptor A. With a portfolio of 11 patents, his work aims to unlock new methodologies for diagnosing and treating diseases linked to IL-17 signaling pathways.

Latest Patents

Among his latest innovations, Peschon has developed IL-17 receptor A antigen binding proteins, including antibodies and polynucleotide sequences. These inventions focus on treatments for diseases mediated by IL-17 receptor A activation. Crucial to his work are the neutralizing determinants on IL-17 receptor A and the corresponding antibodies that target these determinants. By providing compositions and methods for therapy and diagnosis, Peschon’s inventions have the potential to revolutionize approaches to conditions affected by IL-17 signaling.

Career Highlights

Peschon has built an impressive career within well-known biotechnology companies, including Amgen Inc. and Kirin-Amgen, Inc. His extensive research and development experience highlight his role as a leading figure in biopharmaceutical innovations. Over the years, his patents have contributed to advancements in targeted therapies that can transform patient care.

Collaborations

Throughout his career, Jacques J Peschon has collaborated with notable professionals in the field, including Joel E Tocker and James F Smothers. These collaborations underscore the importance of teamwork and shared expertise in driving forward the development of crucial medical technologies.

Conclusion

Jacques J Peschon’s innovations represent a significant leap in the understanding and treatment of diseases associated with IL-17 receptor A. His 11 patents not only reflect his dedication to advancing medical science but also contribute to the broader landscape of biotechnology innovations, marking him as a distinguished inventor in the field.